Skip to main navigation
Skip to search
Skip to main content
Icahn School of Medicine at Mount Sinai Home
Help & FAQ
Link opens in a new tab
Search content at Icahn School of Medicine at Mount Sinai
Home
Profiles
Research units
Publications & Research Outputs
Press/Media
Gene therapy for the respiratory manifestations of cystic fibrosis
Robert J. Korst
, Noel G. Mcelvaney
, Chin Shyan Chu
, Melissa A. Rosenfeld
, Andrea Mastrangeli
, John Hay
, Steven L. Brody
, N. Tony Eissa
, Claire Danel
, H. Ari Jaffe
, Ronald G. Crystal
Icahn School of Medicine at Mount Sinai
Research output
:
Contribution to journal
›
Article
›
peer-review
37
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Gene therapy for the respiratory manifestations of cystic fibrosis'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Gene Therapy
100%
Cystic Fibrosis
100%
Cystic Fibrosis Transmembrane Conductance Regulator
100%
Respiratory Manifestations
100%
Complementary DNA (cDNA)
62%
Airway Epithelium
37%
National Institutes of Health
25%
Normal Human
25%
Airway Epithelial Cells
25%
Lung Function
12%
Airway
12%
Phase I Trial
12%
Safety Data
12%
Heart-lung
12%
Institutional Review Board
12%
Recurrent Infection
12%
Human Trials
12%
Chronic Inflammation
12%
Efficacy Data
12%
Mucus
12%
Heart Blood
12%
National Heart
12%
Airway Epithelial
12%
Experimental Animals
12%
Replication-deficient
12%
Risk to Humans
12%
Epithelial Surface
12%
Adenovirus Type 5
12%
Recombinant Adenovirus
12%
Biosafety
12%
Recombinant DNA Advisory Committee
12%
Parental Genes
12%
Medicine and Dentistry
Cystic Fibrosis
100%
Gene Therapy
100%
Cystic Fibrosis Transmembrane Conductance Regulator
100%
Complementary DNA
62%
In Vitro
25%
Regulator Gene
25%
Lung
25%
Airway Epithelial Cell
25%
Adenoviridae
12%
Mucus
12%
Clinical Study
12%
Phase I Trials
12%
Chronic Inflammation
12%
Recurrent Infection
12%
Serotype
12%
Recombinant
12%
Recombinant DNA
12%
Pharmacology, Toxicology and Pharmaceutical Science
Cystic Fibrosis
100%
Cystic Fibrosis Transmembrane Conductance Regulator
100%
Complementary DNA
62%
Normal Human
25%
Adenoviridae
12%
Clinical Study
12%
Phase I Trials
12%
Recombinant
12%
Chronic Inflammation
12%
Recurrent Infection
12%
Preclinical Study
12%
Experimental Animal
12%
Recombinant DNA
12%